No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 7.2x · 10Y median 7.8x · 41st percentile · as of Oct 5, 2026
Annualized revenue (TTM) · by quarter, last 9
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T13:25:36.018Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Beta Bionics, Inc. (BBNX) stock was $18.95 as of Oct 5, 2026, 4:00 PM EDT, down 0.05% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -14.8%
Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin.
Medical - Devices · Irvine, CA
Next Earnings Date
Oct 27, 2026
21 days away
EPS Estimate
-0.53
Revenue Est.
$34.78M
Last Quarter Results
EPS
$-0.36
vs Estimate
$-0.56
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1BBNX | $852.55M | $18.95 | -0.05% | -14.80% | N/A | N/A | N/A |
| 2JBIO | $856.30M | $14.07 | -0.35% | +58.45% | -52.65% | N/A | vs BBNX |
| 3ALMS | $844.28M | $6.84 | -0.15% | +69.72% | N/A | N/A | vs BBNX |
| 4APMD | $866.15M | $21.75 | +1.12% | N/A | N/A | N/A | vs BBNX |
| 5GLUE | $867.60M | $10.27 | -2.19% | +32.51% | -12.32% | N/A | vs BBNX |
| 6ARDX | $837.43M | $3.39 | +1.50% | -35.42% | +20.95% | -0.20% | vs BBNX |
forward FY estimate
N/A
$32.01M
vs Estimate
$31.46M
Consensus Rating
Based on 12 analysts
Average Price Target
$23.28
+22.9% upside
Low
$16.00
Current
$18.95
High
$30.40
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.54 | $-0.53 | $-0.51 | 3 |
| Quarter ending Dec 2026 | $-0.53 | $-0.50 | $-0.43 | 2 |
| Quarter ending Mar 2027 | $-0.61 | $-0.50 | $-0.41 | 1 |
| Quarter ending Jun 2027 | $-0.63 | $-0.51 | $-0.42 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-2.11 | $-2.05 | $-1.96 | 6 |
| FY 2027 | $-2.75 | $-2.14 | $-1.73 | 6 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $34.41M | $34.78M | $35.00M | 7 |
| Quarter ending Dec 2026 | $26.65M | $32.22M | $35.18M | 7 |
| Quarter ending Mar 2027 | $30.79M | $36.06M | $42.05M | 3 |
| Quarter ending Jun 2027 | $35.66M | $41.76M | $48.70M | 3 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $120.27M | $126.68M | $130.13M | 9 |
| FY 2027 | $172.78M | $182.15M | $192.58M | 9 |
